To identify the risk factors and attributable mortality associated with superinfections in febrile neutropenic patients with hematologic malignancies, we prospectively evaluated 333 episodes of fever and neutropenia by means of univariate and multivariate analyses. Superinfection was defined as any infection either occurring during antibiotic therapy or developing within 1 week after discontinuation of antibiotic therapy. Of 333 episodes, 46 (13.8%) were defined as superinfection; these episodes occurred in 46 patients. The risk factors for superinfection in the multivariate analysis were longer duration of profound neutropenia (P < .0001), lack of use of quinolones as prophylaxis (P < .0001), presence of a central venous catheter (P = .02), and persistence of fever after 3 days of antibiotic therapy (P = .02). The crude mortality rate among patients with superinfection was 48%, and the attributable mortality rate was 24% (95% confidence interval, 3%-45%). Identifying risk factors for superinfections in neutropenic patients might allow clinical practices to reduce the negative impact of this complication. 
few studies have assessed the impact of superinfections in the prognosis of neutropenic patients with cancer. In this study, we analyzed the frequency, etiology, risk factors, and attributable mortality associated with superinfections in neutropenic patients with cancer.
Patients and Methods
Between July 1987 and December 1994, we prospectively evaluated all episodes of fever and neutropenia in patients with hematologic malignancies at two university hospitals in Brazil. The clinical course of the episodes was recorded in a database file. Fever was defined as two or more axillary temperature readings of >38°C in a 24-hour period or as a single reading of _^-38.5°C. Patients were considered to be neutropenic if their neutrophil count was <500/mm 3 or if their granulocyte count was >500/mm3 but decreased progressively and was expected to be <500/mm3 within 24-48 hours.
Until 1988, antibacterial prophylaxis was not given. During 1988, we began to prescribe quinolone therapy routinely to all neutropenic patients who were older than 15 years of age. Until August 1992, antifungal prophylaxis (oral nystatin, ketoconazole, or itraconazole) was used according to the personal preferences of the physicians involved in the study. Thereafter, a prospective, randomized study comparing itraconazole with placebo was started.
Following an initial clinical and laboratory evaluation, empirical antibiotic therapy was started for every febrile neutropenic patient. Fever along with neutropenia was the only indication for the introduction of antibiotic therapy in the present study, The antibiotic combination consisted of ceftazidime and amikacin in most cases; inclusion of a third antibiotic (agents active against gram-positive organisms or anaerobes) was dic-tated by clinical findings. Response to antibiotic therapy was evaluated on day 4, on day 6, and at the end of the treatment. For patients who were still febrile on day 4 and were not receiving a third antibiotic, an agent providing coverage for gram-positive organisms was added to the regimen. If fever persisted until day 7, therapy with intravenous amphotericin B was started. Antibiotic administration and antifungal therapy were continued until the granulocyte count was > 1,000/mm 3 .
Superinfection was defined as any infection either occurring during antibiotic therapy or developing within 1 week after discontinuation of antibiotic therapy. All infections were microbiologically documented. If a microorganism was identified in the beginning of the febrile episode, the superinfection by definition had to be caused by a different agent. Superficial fungal infections, such as oral thrush, were excluded from analysis.
For the assessment of risk factors, we compared the episodes of superinfection with all episodes of neutropenia and fever without superinfection occurring in the same cohort. The following variables were evaluated: age, gender, duration of hospitalization before fever, presence of a central venous catheter, antibacterial and antifungal prophylaxes, underlying disease and status of underlying disease, classification of initial infection (fever of unknown origin, clinically and microbiologically documented with or without bacteremia), response to treatment, duration of neutropenia (<500 neutrophils/mm 3 ), and profound neutropenia (< 100 neutrophils/mm 3 ). Following the univariate analysis, a stepwise multivariate analysis was performed.
For the determination of attributable mortality, each patient with superinfection (case) was matched to the most suitable control by using the independent variables identified in the stepwise logistic regression analysis as the matching parameters. The attributable mortality rate was determined by subtracting the crude mortality rate among the controls from that among the cases [6] .
In the comparison of dichotomous variables, the P value (two-tailed) was calculated by using Fisher's exact test or the x2 test. For continuous variables, the P value was calculated by means of the Wilcoxon rank-sum test. After the univariate analysis, all factors were analyzed in a multivariate stepwise logistic regression analysis. All variables with P values of <.1 in the univariate analysis were included in the regression model.
Results
During the study period, we treated 333 episodes of fever and neutropenia in 189 patients. Of the 333 episodes, 46 (13.8%) were defined as superinfections; these episodes occurred in 46 patients. The median age of the patients with superinfection was 19 years (range, 1-64 years). Twenty-three patients had acute myeloid leukemia; 17, acute lymphocytic leukemia; 2, myelodysplastic syndrome; 3, non-Hodgkin's lymphoma; and 1, Hodgkin's disease. No patient had undergone bone marrow transplantation. Patients with acute myeloid leukemia had more superinfections during remission induction therapy than during relapse (74% vs. 26%, respectively), whereas patients with acute lymphocytic leukemia had superinfections more frequently during relapse than during remission induction therapy (71% vs. 29%, respectively; P = .01).
Twenty-six patients had central venous catheters (15 of which were tunneled). Thirty patients received antibacterial prophylaxis (quinolones, 15; trimethoprim-sulfamethoxazole, 15), and 33 received antifungal prophylaxis (azoles, 16). The initial empirical antibiotic regimen was ceftazidime and amikacin for 13 patients; ceftazidime, amikacin, and an antibiotic active against gram-positive organisms for 19 (vancomycin, 3; teicoplanin, 3; and oxacillin, 13); cephalothin, amikacin, and carbenicillin for 8; and imipenem and amikacin for 6.
The etiologic agents of the superinfections are listed in table 1. The bloodstream was the source of the microorganism in 41 cases, including all bacterial superinfections. The other sources were fungal sinusitis in three cases and pulmonary aspergilloma in two cases. Fungi were responsible for 67% (31) of the superinfections; the mortality rate associated with these infections was 52%. In nine of these cases, the infection was due to both bacteria (gram-positive bacteria, two; gramnegative bacteria, seven) and fungi. Three of these patients died, two of mixed infection with Candida and Klebsiella species and one of mixed infection with Candida species and Enterococcus faecalis. All patients with fusarium infection died. Fifteen infections were due to a single bacterium (gram-positive organism, six; gram-negative organism, nine). Five of the nine patients with infections due to gram-negative organisms died; all of these bacteria were resistant to the antibiotics administered. The organisms were Enterobacter cloacae (3 cases), Klebsiella species (1), and Escherichia coli (1) . The empirical antibiotic regimen was carbenicillin, amikacin, and cephalothin in four cases and ceftazidime, amikacin, and oxacillin in one case. Ten of the 16 gram-negative bacteria isolated were resistant to at least one of the antibiotics administered. Patients who received antibacterial prophylaxis with quinolones had fewer superinfections due to gram-negative bacteria than did patients who did not receive quinolone prophylaxis (13% vs. 45%, respectively; P = .07).
The risk factors for superinfection in the univariate analysis (table 2) were longer duration of profound neutropenia (<100 neutrophils/mm3; P < .0001), persistence of fever on day 7 of antibiotic therapy (P < .0001), presence of a central venous catheter (P < .0001), microbiologically documented infection with bacteremia (P = .0009), longer duration of neutropenia (P = .001), persistence of fever on day 4 of antibiotic therapy (P = .004), lack of use of quinolones as prophylaxis (P = .009), longer duration of hospitalization before the first episode of fever (P = .01), and younger age (P = .02). All these variables plus underlying disease during relapse (P = .06) were included in the stepwise logistic regression analysis.
In the multivariate analysis (table 3) , only four variables were predictive for superinfection: longer duration of profound neutropenia (P < .0001), lack of use of quinolones as prophylaxis (P < .0001), presence of a central venous catheter (P = .02), and persistence of fever after 3 days of antibiotic therapy (P = .02).
In the determination of attributable mortality, matching of the 46 controls by means of the four variables identified as risk factors was successful for the duration of profound neutropenia in 96% of cases, the use of quinolones as prophylaxis in 98%, the presence of a central venous catheter in 80%, and the persistence of fever after 3 days of antibiotic therapy in 80%. The overall success of matching was 86%. Twenty-two of the 46 patients with superinfection died; the crude mortality rate among the cases was 48%, while the crude mortality rate among the controls was 24% (P = .02). The attributable mortality rate was 24% (95% CI, 3%-45%). The risk ratio was 2.0 (95% CI, 1.10-3.63).
Discussion
The occurrence of superinfection is a major problem in the management of neutropenic patients [7] . Nevertheless, there are very few studies on this issue. The frequency of superinfections in different clinical trials comparing the efficacy of antibiotic therapy for neutropenic patients [8] [9] [10] varied between 1% and 23%. This wide variation may be related to differences in potential risk factors for the patients in the different studies.
The use of prophylactic antibiotics may be one of these factors. Richard et al. [11] showed that the previous use of quinolones by immunosuppressed patients was the only risk factor for the isolation of quinolone-resistant bacteria in cases of nosocomial infections. Other researchers [12] reported the emergence of quinolone-resistant E. coli causing bacteremias in neutropenic patients.
We observed different frequencies of superinfections in patients with acute lymphoid leukemia and those with acute myeloid leukemia: superinfection was more common in patients with acute lymphoid leukemia during relapse and in patients with acute myeloid leukemia during remission induction therapy. This finding may be related to the chemotherapeutic regimens employed in the two situations.
Remission induction therapy for acute lymphoid leukemia is seldom associated with prolonged neutropenia, whereas patients with relapses are treated with more myelotoxic regimens, including high doses of cytarabine. On the other hand, in patients with acute myeloid leukemia, one could expect more superinfections during relapse. However, in our experience, patients' clinical conditions are generally better during relapse than following their diagnosis. This finding may be related to the fact that the diagnosis of leukemia in most of our patients was delayed [13] .
In our study, fungi were responsible for 67% of the superinfections. This finding was not unexpected since prolonged neutropenia is one of the most important risk factors for fungal infections [14] . Serra et al. [15] evaluated the frequency, risk factors, and etiology of superinfections in 631 patients with hematologic malignancies. Fungi caused 24.7% of the superinfections, followed by gram-negative bacteria (antibioticresistant) and gram-positive bacteria. In our study, most of the gram-negative organisms causing superinfection were also resistant to at least one of the antibiotics administered.
The mortality rate associated with the different etiologic agents causing superinfection varied: 59%, fungal infections; 55%, bacteremia due to gram-negative bacteria; 33%, mixed infections due to fungi and bacteria; and 17%, bacteremia due to gram-positive bacteria. It is not surprising that methicillinresistant S. aureus caused the only death among patients with bacteremia due to gram-positive bacteria. Bacteremia due to methicillin-resistant S. aureus is associated with a higher mortality rate than is bacteremia due to methicillin-susceptible S. aureus [16] .
Although it has been postulated that superinfections are most likely to occur in patients with prolonged neutropenia, the role of this risk factor and others is not clear. In the study by Serra et al. [15] , only univariate analyses were performed. The researchers identified duration and severity of neutropenia as risk factors. Pizzo et al. [17] also established a correlation between duration of neutropenia and the risk for superinfection. The frequency of superinfection was zero when the duration of neutropenia was <7 days and 47% when neutropenia was more persistent.
On the other hand, Feld et al. [18] analyzed 154 episodes of superinfection in 644 patients and did not find the duration of neutropenia to be an independent risk factor in a multivariate analysis. These investigators identified duration of treatment, response to treatment, and lack of use of antiviral prophylaxis as risk factors for superinfection. In our study, duration of neutropenia (<500 neutrophils/mm3) was a risk factor only in the univariate analysis, but duration of profound neutropenia (< 100 neutrophils/mm3) was strongly related to the development of superinfection in the univariate as well as the multivariate analysis. These data suggest that strategies for reducing the duration of neutropenia might have an impact on decreasing the frequency of superinfections.
The use of central venous catheters has been associated with the development of both bacteremia and fungemia [3, 19] . In our study, the presence of a central venous catheter was associated with the development of superinfection. The overall incidence of catheter-related infections at our center was 2.8 infectious episodes per 1,000 catheter-days in a prospective evaluation (M. N., author's unpublished data), a figure that is not different from those at other centers [20] . Another variable that was associated with superinfection was the persistence of fever after 3 days of empirical antibiotic therapy. We [21] previously identified this variable as a marker for nonresponse to antibiotic therapy as well as for death in a cohort of patients treated with ceftazidime and amikacin.
The use of quinolones as prophylaxis for neutropenic patients has been evaluated in the last decade. A randomized, multicenter trial [22] demonstrated that the use of quinolones reduces the frequency of bacteremias due to gram-negative organisms, although no impact on survival was observed. On the other hand, the development of bacteremia due to quinolone-resistant gram-negative strains was recently described in patients taking quinolones as prophylaxis [12] . Therefore, it is feared that the use of quinolones might increase the risk of superinfections, and many investigators do not recommend their use [23] . However, in our study, the lack of use of quinolones as prophylaxis was associated with an increased risk of superinfection in both the univariate analysis and the multivariate analysis.
In a previous evaluation of the impact of the use of quinolones as prophylaxis for our patients [24] , we reported a significant reduction in the frequency of bacteremias, including those due to gram-negative organisms; in this nonrandomized, sequential comparison, the frequency of bacteremia due to gram-negative bacteria was 6% among patients who received quinolone prophylaxis and 38% among patients who did not. This association between quinolone use and lower risk for superinfection is interesting and adds to the current controversy regarding quinolone prophylaxis for neutropenic patients.
The response to treatment in secondary bacterial infections is lower than that in primary bacterial infections [5] . However, little is known about the real impact of superinfections on morbidity and mortality rates among neutropenic patients. In the present study, we used the estimation of the attributable mortality rate (the crude mortality rate among cases subtracted from the crude mortality rate among matched controls) as a measure. In studies of nosocomial bloodstream infections, controls are usually matched to cases in terms of age, sex, duration of hospitalization, and underlying disease [6] .
We used a matching technique that took into account the risk factors identified in the multivariate analysis, so that cases and controls were very similar regarding these risk factors. Matching was >95% successful for the two most important variables (duration of profound neutropenia and use of quinolones as prophylaxis). This estimation showed that the attributable mortality rate associated with superinfection is high (24%). Considering the better control of initial febrile episodes in neutropenic patients and the advances in the treatment of neoplastic diseases, the negative impact of a superinfection is very high.
In summary, superinfection in neutropenic patients is common, and in most cases, it is caused by fungi and resistant gramnegative bacteria. The risk factors identified in our multivariate analysis were longer duration of profound neutropenia, lack of use of quinolones as prophylaxis, use of central venous catheters, and persistence of fever after 3 days of antibiotic therapy. The attributable mortality rate was high. Identifying risk factors for superinfections in neutropenic patients might allow clinical practices to reduce the negative impact of this complication.
